Free Newsletter
Budget tightening raises concerns at NCI
A variety of groups are criticizing efforts by the Bush administration to slice spending at the National Cancer Institute by 1 percent. The move would represent the second year in a row for cuts at the NCI. Top researchers say that the strategy could ultimately undercut the quality of research in oncology at the same time progress in the field is cutting the number of deaths from cancer in the U.S. for the first time. The head of the NCI, John Niederhuber (photo), is concerned that he could lose up to 10 percent of his budget by ax-wielding legislators. Members of the administration, though, note that overall spending at the NCI has doubled in the past 10 years.
The latest news comes on top of a report that NIH Director Elias Zerhouni is pooling five percent of its money into a special fund supporting research that cuts across the NIH's research groups. Fears are being raised that some of the internal fiefdoms at the NIH could lose big if Zerhouni gains power over the budget.
- read the report on the NCI from USA Today
ALSO: The biomedical group FASEB is calling for enough government funds to make up for inflation in their field. Cutbacks at the NIH, they say, threaten the country's leading position in biotechnology. Report
Comments
Once again this administration proves itself to be useless. Less than 1500 new cases of AIDS were reported in 2006 but 169,000 new cases and 10 million Americans die and are fighting cancer and this administration wants to cut funding.We have only ourselves to blame. we put them in office.
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceBiotech Research email newsletter for FREE!
Be the first to comment